ESH 2017 | Selecting AML patients for intensive treatment
Marina Konopleva
• 5 Oct 2017
Many variables are involved in selecting the type of treatment that a patient can receive. Speaking from the International Conference on Acute Myeloid Leukaemia 2017, Estoril, Portugal by the European School of Haematology (ESH), Marina Konopleva, MD, PhD of the MD Anderson Cancer Center, Houston, TX, discusses the key factors involved in selecting acute myeloid leukemia patients for intensive treatment, and the issues with this. Dr Konopleva also provides an overview of the treatment options available to patients, referencing a recent venetoclax trial (NCT02993523).
